PE20091973A1 - Anticuerpos modificadores de enfermedades cancerosas - Google Patents
Anticuerpos modificadores de enfermedades cancerosasInfo
- Publication number
- PE20091973A1 PE20091973A1 PE2009000695A PE2009000695A PE20091973A1 PE 20091973 A1 PE20091973 A1 PE 20091973A1 PE 2009000695 A PE2009000695 A PE 2009000695A PE 2009000695 A PE2009000695 A PE 2009000695A PE 20091973 A1 PE20091973 A1 PE 20091973A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- isolated
- cancer
- cancer disease
- disease modifying
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN ANTICUERPO MONOCLONAL AISLADO, UN ANTICUERPO HUMANIZADO DEL ANTICUERPO MONOCLONAL AISLADO, UN ANTICUERPO QUIMERICO DEL ANTICUERPO MONOCLONAL AISLADO O ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS (CDMAB) DE LOS MISMOS, QUE SE CARACTERIZAN POR LA CAPACIDAD DE INHIBIR COMPETITIVAMENTE LA UNION DE DICHO ANTICUERPO MONOCLONAL AISLADO A SU ANTIGENO OBJETIVO. DICHO ANTICUERPO AISLADO ES CONJUGADO CON PORCIONES CITOTOXICAS COMO UN ISOTOPO RADIACTIVO, ENZIMAS, COMPUESTOS RADIOACTIVOS Y CELULAS HEMATOGENAS. REFIERE TAMBIEN QUE DICHO ANTICUERPO AISLADO ACTIVA EL COMPLEMENTO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5437208P | 2008-05-19 | 2008-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091973A1 true PE20091973A1 (es) | 2010-01-15 |
Family
ID=41339689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000695A PE20091973A1 (es) | 2008-05-19 | 2009-05-18 | Anticuerpos modificadores de enfermedades cancerosas |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090304579A1 (es) |
AR (1) | AR071847A1 (es) |
PE (1) | PE20091973A1 (es) |
TW (1) | TW200948382A (es) |
WO (1) | WO2009140755A1 (es) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2471206A1 (en) * | 2001-12-21 | 2003-07-10 | Arius Research, Inc. | Individualized anti-cancer antibodies |
-
2009
- 2009-05-15 US US12/467,110 patent/US20090304579A1/en not_active Abandoned
- 2009-05-15 WO PCT/CA2009/000665 patent/WO2009140755A1/en active Application Filing
- 2009-05-18 PE PE2009000695A patent/PE20091973A1/es not_active Application Discontinuation
- 2009-05-18 TW TW098116441A patent/TW200948382A/zh unknown
- 2009-05-19 AR ARP090101798A patent/AR071847A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20090304579A1 (en) | 2009-12-10 |
TW200948382A (en) | 2009-12-01 |
WO2009140755A1 (en) | 2009-11-26 |
AR071847A1 (es) | 2010-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6140062A2 (es) | Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas | |
CL2021002645A1 (es) | Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos. (divisional de solicitud 201900726) | |
CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
BR112017027498A2 (pt) | anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença. | |
CO2019003923A2 (es) | Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos | |
AR096015A1 (es) | Conjugados de fármacos con anticuerpos | |
PE20180798A1 (es) | Constructos de anticuerpos biespeficos que se unen a mesotelina y cd3 | |
NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения | |
AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
CO6241160A2 (es) | Anticuerpos anti-cd44 quiméricos y humanizados que median la citotoxicidad de celulas de cancer | |
AR070168A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos | |
PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
PE20140614A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
AR064337A1 (es) | Anticuerpos humanos que enlazan con cd19 y sus usos | |
UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
CO6270369A2 (es) | Nuevos anticuerpos especificos de los peptidos beta -amiloides y sus usos como agentes de diagnostico o drogas | |
AR104987A1 (es) | Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos | |
BRPI0817427A8 (pt) | anticorpo anti-bst2 | |
BR112016007232A2 (pt) | anticorpos anti-epcam e métodos de uso | |
AR113223A1 (es) | Anticuerpo monoclonal para pd-l1 | |
AR094960A1 (es) | Anticuerpos de quimiocina pan-elr⁺ cxc | |
PE20220004A1 (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh | |
PE20140756A1 (es) | Anticuerpos que se unen a bst1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |